TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01220180

Intervention type: DRUG
Intervention: pregabalin (Lyrica)
Description: Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.

Intervention type: DRUG
Intervention: pregabalin (Lyrica)
Description: Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered.

Intervention type: DRUG
Intervention: pregabalin (Lyrica)
Description: The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
Study: NCT03462381

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein
Description: Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
Study: NCT00857519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan, Carboplatin
Description: Intra-arterial chemotherapy.
Study: NCT02385435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Caudal Bupivacaine 2 mg/kg single shot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 1μg.kg-1
Description: Caudal dexmedetomidine 1μg.kg-1, single shot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 2μg.kg-1
Description: Caudal dexmedetomidine 2μg.kg-1, single shot
Study: NCT00542061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: half-yearly monitoring routine
Description: A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
Study: NCT02086422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT00629798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
Description: Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients \> or = to 4 years of age or 1.0 mg/kg IV for patients \< 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
Study: NCT01801852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKT cells
Study: NCT03135977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib, Etoposide
Description: Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
Study: NCT03281304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,500 5 mg
Description: CP-690,550 5 mg tablet BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 10 mg
Description: CP-690,550 10 mg tablet BID
Study: NCT00801021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frio Mouth Rinse
Description: Rinse with 15ml twice daily then expectorate
Study: NCT02684188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced rural discharge and transition
Description: While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
Study: NCT02161419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roniciclib (BAY1000394)
Description: Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
Study: NCT04196673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon SN60WF
Description: Implantation of an intraocular lens Alcon SN60WF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hoya Vivinex
Description: Implantation of an intraocular lens Hoya Vivinex
Study: NCT03693781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 1 MG Oral Tablet
Description: Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 1 MG Oral Tablet
Description: Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (\>70 kg or \<71 kg) for 30 weeks of duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Corresponding tablets for 30 weeks
Study: NCT03389178

Intervention type: DIAGNOSTIC_TEST
Intervention: Cohen Perceived Stress Scale-10 (PSS-10)
Description: Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control

Intervention type: DIAGNOSTIC_TEST
Intervention: Cohen Perceived Stress Scale-10 (PSS-10)
Description: Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score \< 19 will be entered into Phase II as control
Study: NCT00527332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 5 mg/mL, 4 mL intrathecally as a single dos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.4 mg/mL; 0.5 mL intrathecally as a single dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
Study: NCT01493921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle gel
Description: Patient wil be instructed to self-apply approximately 0.3\~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
Study: NCT01005602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digoxin Dosing per Nomogram
Description: Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.

Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin
Description: All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
Study: NCT03040453

Intervention type: DEVICE
Group type: OTHER
Intervention: Microwave ablation

Intervention type: DEVICE
Group type: OTHER
Intervention: Irreversible electroporation
Study: NCT00667953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Gleevec (600 mg) daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar
Description: Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
Study: NCT03523455

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Aid IPS (Iron Protein Succinylate)
Description: Taken orally in capsule form

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Taken orally in capsule form
Study: NCT02404480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
Study: NCT05467631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical oil application
Description: Topical Comparison

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical oil application
Description: Topical Comparison
Study: NCT01320501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All patients will receive: TarcevaTM 150mg/day PO.
Study: NCT02861014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
Study: NCT02174978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP012 with AS01B adjuvant system
Description: Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP012 with AS01B adjuvant system
Description: Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P falciparum Controlled Human Malaria Infection (CHMI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P falciparum Controlled Human Malaria Infection (CHMI)

Intervention type: OTHER
Group type: OTHER
Intervention: P falciparum Controlled Human Malaria Infection (CHMI)
Study: NCT00831194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized diet plan and PDA self reporting.
Description: Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
Study: NCT01544894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 60 mg/d for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strontium ranelate
Description: 2 g/d, for one year
Study: NCT02205255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02414594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-APO(a)-LRx
Description: Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT04131036

Intervention type: OTHER
Intervention: assessment of joint health and bone density
Description: We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.

Intervention type: OTHER
Intervention: assessment of joint health and bone density
Description: We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
Study: NCT01558999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High concentration SI-614
Description: 1 drop in each eye 4 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low concentration SI-614
Description: 1 drop in each eye 4 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye 4 times a day
Study: NCT00299676

Intervention type: DRUG
Intervention: Galantamine (Reminyl)
Description: Use of Reminyl according to approved NZ data sheet
Study: NCT01623609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
Study: NCT03905577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Observation
Description: Action Observation training
Study: NCT03046394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-SACH
Description: Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
Study: NCT03905577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: Motor imagery protocol

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Action observation
Description: Placebo Action Observation
Study: NCT03405922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 40 mL Saline 0.9%
Description: Injection of 40 mL 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mL Ropivacain 0.5%
Description: Ropivacaine Hcl 0.5% Injection 40 mL
Study: NCT03046394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-DER
Description: Dynamic Motion by Otto Bock, advertised for activity category 2-3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A-DER
Description: Triton by Otto Bock, advertised for activity category 3-4
Study: NCT00000250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O
Description: Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
Study: NCT03742193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD regimen
Description: One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken.
Study: NCT00527332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronbromid
Description: 0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 5 mg is given IV (intravenously) before end of surgery
Study: NCT04309058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D drops
Description: Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
Study: NCT04427449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD44v6-specific CAR gene-engineered T cells
Description: 4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight
Study: NCT02147769

Intervention type: DEVICE
Intervention: NIRS monitoring
Description: All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
Study: NCT00865319

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)
Description: one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18 F fluorodeoxyglucose
Description: single injection of 18F FDG (range 10-20mCi)
Study: NCT03597061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Start to Feeding
Description: The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
Study: NCT02160145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan (OPC-41061)
Description: Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Study: NCT00566254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: 8mg/kg per day for approximately 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02635997

Intervention type: DRUG
Intervention: antiresorptive therapy
Study: NCT02992535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulse Light Energy delivery (IPL)
Study: NCT03731078

Intervention type: OTHER
Intervention: CBT Informed physical therapy Intervention
Description: The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.